Last reviewed 2026-04-23 · How we verify

Ten-days oseltamivir

Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread.

Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread. Used for Influenza A and B infection treatment, Influenza prophylaxis.

At a glance

Mechanism of action

Oseltamivir inhibits viral neuraminidase, an enzyme on the surface of influenza viruses that cleaves sialic acid receptors and allows newly formed virus particles to escape from infected cells. By blocking this enzyme, the drug prevents viral release and transmission to neighboring cells, thereby reducing viral load and shortening the duration of infection. The 10-day regimen represents an extended treatment course compared to standard 5-day dosing.

Approved indications

• Influenza A and B infection treatment
• Influenza prophylaxis

Common side effects

• Nausea
• Vomiting
• Headache
• Abdominal pain

Key clinical trials

• Post-exposure Influenza Prophylaxis (PHASE3)
• Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
• Randomised Evaluation of COVID-19 Therapy (PHASE3)
• Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Ten-days oseltamivir CI brief — competitive landscape report
• Ten-days oseltamivir updates RSS · CI watch RSS
• UMC Utrecht portfolio CI